These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7606966)

  • 21. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
    Lee JS; Kim HR; Lee CY; Shin M; Shim HS
    Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer.
    Yamashita S; Chujo M; Miyawaki M; Tokuishi K; Anami K; Yamamoto S; Kawahara K
    J Exp Clin Cancer Res; 2009 Feb; 28(1):22. PubMed ID: 19228369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invited commentary.
    Korst RJ
    Ann Thorac Surg; 2006 Jul; 82(1):248. PubMed ID: 16798223
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
    Yang SL; Ren QG; Wen L; Hu JL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer.
    Wang HH; Wang YC; Wu DW; Hung CS; Chen CY; Lee H
    Tumour Biol; 2017 Apr; 39(4):1010428317694316. PubMed ID: 28378642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of genetic and molecular events in the pathogenesis of lung cancer.
    Johnson BE; Kelley MJ
    Chest; 1993 Jan; 103(1 Suppl):1S-3S. PubMed ID: 8380130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
    Mitsudomi T; Steinberg SM; Oie HK; Mulshine JL; Phelps R; Viallet J; Pass H; Minna JD; Gazdar AF
    Cancer Res; 1991 Sep; 51(18):4999-5002. PubMed ID: 1654209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma.
    Xiao GQ; Li F; Findeis-Hosey J; Hyrien O; Unger PD; Xiao L; Dunne R; Kim ES; Yang Q; McMahon L; Burstein DE
    Hum Pathol; 2015 Nov; 46(11):1607-15. PubMed ID: 26297253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.
    Han Y; Tian H; Chen P; Lin Q
    Oncotarget; 2017 Apr; 8(14):22730-22740. PubMed ID: 28186994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
    Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
    Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
    Dworakowska D; Jassem E; Jassem J; Peters B; Dziadziuszko R; Zylicz M; Jakóbkiewicz-Banecka J; Kobierska-Gulida G; Szymanowska A; Skokowski J; Roessner A; Schneider-Stock R
    Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.